LACOG 0221 – IHOC

OC Oncoclínicas Curitiba – IHOC

Mama

LACOG 0221 – Real world data of first line treatment of hormone receptor positive, HaER2 negative metastatic breast cancer in Brazil.

Center

OC Oncoclínicas Curitiba – IHOC

Principal investigator

Aline Vieira

Email

aline.vieira@medicos.oncoclinicas.com

Inclusion criteria

Women ≥18 years old;
Hormone receptor positive(HR+)and HER-2 negative(HER-2 -) invasive breast cancer: RH+ defined as 1% to 100% of tumor cores positive for Estrogen Receptor (ER)and/or Progesterone Receptor (PR) as per ASCO/CAP 2020 Guidelines-or Allred score ≥3 HER-2-defined as immunohistochemistry (IHC)result 0/1+ or 2+ with negative ISH as per ASCO/CAP 2018 guidelines;
Diagnosed with de novo or recurrent metastatic breast cancer between Jan 2018 and Dec 2020.

Exclusion criteria

Câncer de mama masculino;
Primeira linha de tratamento para câncer de mama metastáticorecebida através de ensaio clínico.

Coordinator(s)

Aline Vieira
Share
Or share the link
Link copied to your desktop.